LY 2787106Alternative Names: JABA; LY2787106
Latest Information Update: 10 Feb 2015
At a glance
- Originator Eli Lilly
- Class Antianaemics; Monoclonal antibodies
- Mechanism of Action Hepcidin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 31 Jan 2015 Discontinued - Phase-I for Anaemia in USA (IV)
- 31 Oct 2009 Phase-I clinical trials in Anaemia in USA (IV)